The aim of the present study was to prepare sustained release matrix tablets of lornoxicam to make drug in sustained form so as to prolong its elimination time for the effective treatment of rheumatoid arthritis, and also in the management of ankylosing spondylitis, acute sciatica and low back pain. The present investigation demonstrates that, use of hydrophilic and hydrophobic polymers could be successfully employed for formulating sustained release matrix tablets of Lornoxicam. Optimized formulation containing HPMC K100M and Ethyl cellulose at optimum ratio had successfully sustained the drug release for 24 h. Matrix tablets of optimized batch had in vitro drug release. It was observed that the optimized matrix tablets of optimized batch shows better flow property by studying various pre-compression parameters. Thus, sustained release matrix tablets of Lornoxicam using biocompatible polymers were successfully formulated, evaluated and found to be suitable candidates in extending the release of the drug from the matrix tablets.
INTRODUCTION
A sustained-release dosage form is defined as "any drug or dosage form modification that prolongs the therapeutic activity of the drug"
1
. Development of oral sustained release (SR) tablets of highly water soluble drugs or bioactives has always been a challenge and therefore, opportunity for formulation scientist. Most of these drugs if not formulated properly, may be released at a faster rate resulting in exceeding the maximum therapeutic levels and hence will lead to toxic side effects. Sustained delivery of such drugs ensures improved drug delivery and patient compliance, greater safety and efficacy, desired release kinetics and helps in maintaining the plasma drug concentration within the therapeutic window for extended period of time 
Preformulation work
Identification of drug was done by FTIR Spectrophotometer and all the drug excipients compatibility study was performed. All the ingredients were mixed well in a double cone blender. Lornoxicam was first mixed with the polymer, PVP K30 and directly compressible lactose for 10 min to obtain uniform mixture. Then the mixture was passed through 60#. Finally the mixture was blended with the talc and magnesium stearate. 100 mg tablets were punched by compression machine.
In-process evaluation study 17, 18 Pre-compression parameters
To find out physiochemical properties and release characteristics of the granular blend, all formulations are subjected to pre-formulation studies like bulk density, tapped density, Angle of repose, compressibility index and Hausner's ratio.
Preparation of matrix tablet:
Tablets are prepared by direct compression technique 11, 
12, 19

Evaluation of compressed tablets
The tablets prepared were evaluated for weight variation, disintegration test, dissolution test, thickness, hardness of individual dose and friability.
Weight variation
The weight variation was performed by weighing 20 tablets individually, then individual weight of tablet is compared with average weight of 20 tablets.
Hardness
The hardness of each batch of tablet was checked by using Monsanto hardness tester. The hardness was measured in terms of kg/cm2.
Friability
The friability was determined by first weighing 10 tablets before placing in friability tester (Roche friabilator), which was rotated for 4 min at 25 rpm. After dusting, the remaining weight of tablet was determined.
Thickness
The thickness of tablet was determined by vernier caliper.
Disintegration
17, 18
The test was performed by introducing one tablet in each tube and adds a disc to each tube. Suspend the assembly in the beaker containing purified water and operate the apparatus until the tablet completely disintegrates.
In Vitro Dissolution test 17, 18
In-vitro dissolution studies were carried out using USP XXIII dissolution apparatus type II at 50 rpm. Dissolution test was carried out for a total period of 24 hr using 0.1N HCl (pH 1.2) solution (900 ml) as a dissolution medium at 37 ± 0. 5 º C for first 2 hr and phosphate buffer (pH 6.8) solution (900 ml) solution for the rest of the period.5 ml of sample was withdrawn at predetermined time interval of 1 hr up to 24 hr and replaced with same volume of fresh dissolution medium. The withdrawn samples were filtered and analyzed by UV spectrophotometer at 376 nm using pH 6.8 as a blank. Percentage cumulative drug release was calculated.
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Pre-compression parameters
In-vitro dissolution studies
In-vitro dissolution studies were carried out using USP XXIII dissolution apparatus type II at 50 rpm. Dissolution test was carried out for a total period of 24 hr using 0.1N HCl (pH 1.2) solution (900 ml) as a dissolution medium at 37 ± 0. 5 º C for first 2 hr and phosphate buffer (pH 6.8) solution (900 ml) solution for the rest of the period.5 ml of sample was withdrawn at predetermined time interval of 1 hr up to 24 hr and replaced with same volume of fresh dissolution medium. The withdrawn samples were filtered and analyzed by UV spectrophotometer at 376 nm using pH 6.8 as a blank. Percentage cumulative drug release was calculated. 
Stability studies
The purpose of stability testing is to provide evidence on how the quality of a drug substance or drug product varies with time under influence of various environmental factors such as temperature, humidity and light, and enables recommended storage conditions, retest periods and self-lives to be established.
ICH specifies the length (duration) of study and storage conditions
Accelerated stability studies are testing at 40 º C ± 2 º C / 75 % RH ±.5 % for a specific time period up to 3 months and long term stability studies are testing at 25 º C ± 2 º C / 60 % RH ±5 % for a specific time period up to 12 months. Stability studies were carried out at 40 ± 2 º C / 75 % RH for a specific time period up to 90 days. 
